KEY TAKEAWAYS:

Tulane Ventures invests $125,000 in Beken Bio to advance early cancer detection technology.

Founder and CEO Christopher Millan returns to New Orleans as the company expands operations.

Beken Bio’s AI-driven platform identifies cancer signals earlier than traditional methods.

New funding supports clinical studies, hiring and equipment as the startup prepares for a Series A round.

Tulane Ventures has invested $125,000 in Beken Bio, a biotechnology startup developing early-detection blood tests for aggressive cancers, bringing the company’s founder back to New Orleans as it expands operations. The announcement marks another boost for the region’s growing life-sciences ecosystem.

The company is led by founder and CEO Christopher Millan, Ph.D., a New Orleans native and

See Full Page